Covid-19 man­u­fac­tur­ing roundup: 3 com­pa­nies to col­lab­o­rate on mR­NA vac­cine; Omi­cron-fo­cused vac­cine could be on the way

Gen­Script, Suzhou Abo­gen, and Wal­vax Biotech­nol­o­gy have an­nounced the three com­pa­nies will be col­lab­o­rat­ing on a Covid-19 mR­NA vac­cine project dubbed ABO-O28M.

Wal­Vax will sub­mit a BLA for the project, and Gen­Script will pro­vide ex­clu­sive man­u­fac­tur­ing ser­vices, ac­cord­ing to Asia One.

The project stems form an agree­ment be­tween Abo­gen, the  Acad­e­my of Mil­i­tary Med­ical Sci­ences (AMMS) of the PLA Acad­e­my of Mil­i­tary Sci­ence and Wal­vax, which gained clin­i­cal tri­al ap­proval in June 2020. It was one of the first vac­cine projects ap­proved by Chi­na’s gov­ern­ment, and Gen­Script used its plas­mid GMP man­u­fac­tur­ing to ac­cel­er­ate in­to clin­i­cal tri­als.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER